Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Adaptive immunity to SARS-CoV-2 and COVID-19

(2021) Alessandro Sette et al.   CELL

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

(2021) Vincent Legros et al.   Cellular & Molecular Immunology

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Neutralizing antibody titres in SARS-CoV-2 infections

(2021) Eric H. Y. Lau et al.   Nature Communications

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

(2021) Jianmin Zuo et al.   NATURE IMMUNOLOGY

Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

(2021) Flor M. Munoz et al.   VACCINE

Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective

(2021) Colin D. Funk et al.   Viruses-Basel

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

(2021) Stéphane Marot et al.   Nature Communications

Severe covid-19 pneumonia: pathogenesis and clinical management

(2021) Amy H Attaway et al.   BMJ-British Medical Journal

Correlates of Vaccine-Induced Protection against SARS-CoV-2

(2021) Till Koch et al.   Vaccines

Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization

(2021) Yongjun Sui et al.   Pathogens

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

(2021) Jennifer Hicks et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

(2021) Prabhu S. Arunachalam et al.   NATURE

SARS-CoV-2 evolution and vaccines: cause for concern?

(2021) Thomas C Williams et al.   Lancet Respiratory Medicine

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Development of an antibody cocktail for treatment of Sudan virus infection

(2020) Andrew S. Herbert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

(2020) Alba Grifoni et al.   CELL

Deployment of convalescent plasma for the prevention and treatment of COVID-19

(2020) Evan M. Bloch et al.   JOURNAL OF CLINICAL INVESTIGATION

Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples

(2020) Alessandro Manenti et al.   JOURNAL OF MEDICAL VIROLOGY

Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines

(2020) Paul-Henri Lambert et al.   VACCINE

Approaches and Challenges in SARS-CoV-2 Vaccine Development

(2020) Gabriel Dagotto et al.   Cell Host & Microbe

Lessons for COVID-19 Immunity from Other Coronavirus Infections

(2020) Alan Sariol et al.   IMMUNITY

SARS-CoV-2 Vaccine Development: Current Status

(2020) Gregory A. Poland et al.   MAYO CLINIC PROCEEDINGS

Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

(2020) Jose Gomez-Rial et al.   Infection and Drug Resistance

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

(2020) Brian J Ward et al.   LANCET

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

(2020) Angkana T. Huang et al.   Nature Communications

Emerging Concepts and Technologies in Vaccine Development

(2020) Morgan Brisse et al.   Frontiers in Immunology

Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis

(2020) Meng Wang et al.   BMJ Supportive & Palliative Care

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

(2020) Ventura A. Simonovich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

(2019) Catherine Cohet et al.   VACCINE

Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages

(2019) Alexander I. Makarkov et al.   npj Vaccines

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

(2019) Stéphane Pillet et al.   PLoS One

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

(2018) Randall Hyer et al.   VACCINE

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

(2018) Stéphane Pillet et al.   npj Vaccines

CEPI: preparing for the worst

(2017) Talha Burki   LANCET INFECTIOUS DISEASES

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults

(2016) Stéphane Pillet et al.   CLINICAL IMMUNOLOGY

SARS and MERS: recent insights into emerging coronaviruses

(2016) Emmie de Wit et al.   NATURE REVIEWS MICROBIOLOGY

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

(2016) Oi-Wing Ng et al.   VACCINE

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

(2015) Patricio L. Acosta et al.   Clinical and Vaccine Immunology

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

(2015) Adam Penn-Nicholson et al.   VACCINE

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

(2014) Nathalie Landry et al.   CLINICAL IMMUNOLOGY

Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection

(2014) R. Channappanavar et al.   JOURNAL OF VIROLOGY

Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology

(2014) Gregory A. Grabowski et al.   MOLECULAR GENETICS AND METABOLISM

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

(2014) Brian J. Ward et al.   VACCINE

Follicular Helper CD4 T Cells (TFH)

(2011) Shane Crotty   Annual Review of Immunology

Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study

(2011) F. Tang et al.   JOURNAL OF IMMUNOLOGY

Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses

(2010) Xiaopei Huang et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

(2010) Marc-André D’Aoust et al.   PLANT BIOTECHNOLOGY JOURNAL

Influenza virus-like particles produced by transient expression inNicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice

(2008) Marc-André D’Aoust et al.   PLANT BIOTECHNOLOGY JOURNAL